Moreover, by integrating our data with external target annotation resources, we evaluated the CKI scores based on a number of clinical classifications, such as target development level (TDL),11 which classifies a target based on available target validation knowledge (Tclin, Tchem, Tbio, and Tdark); kinase family class (which corresponds to phylogenecity and substrates); clinical trial data; and MOA (mechanism of action) of approved drugs for each cancer type.1 Here, CHKA is linked to cancer.